Cutler Group’s BridgeBio Pharma BBIO Stock Holding History

Cutler Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,000	Closed	-$9K	–	3612
2023 Q3	$9K	Buy	+1,000	New	+$28.4K	﹤0.01%	2506
2023 Q2	–	Sell	-21,300	Closed	-$3K	–	3567
2023 Q1	$3K	Buy	+21,300	New	+$248K	﹤0.01%	2909
2022 Q4	–	Sell	-2,000	Closed	-$1K	–	4382
2022 Q3	$1K	Buy	2,000 +1,000	+100%	+$10.4K	﹤0.01%	4423
2022 Q2	$1K	Sell	1,000 -15,300	-94%	-$128K	﹤0.01%	4499
2022 Q1	$137K	Sell	16,300 -116,300	-88%	-$1.19M	0.01%	1459
2021 Q4	$771K	Buy	+132,600	New	+$5.61M	0.03%	557
2021 Q2	–	Sell	-2,200	Closed	-$1K	–	5676
2021 Q1	$1K	Buy	+2,200	New	+$144K	﹤0.01%	5128
2020 Q3	–	Sell	-10,000	Closed	-$10K	–	4660
2020 Q2	$10K	Hold	10,000	–	–	﹤0.01%	2845
2020 Q1	$53K	Buy	+10,000	New	+$310K	﹤0.01%	1686

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cutler Group's BBIO Position: Q4 2023 in Review

Cutler Group sold out of BridgeBio Pharma (BBIO) in Q4 2023, closing a stake of 300 shares — an estimated $7K sold.

Cutler Group first reported a position in BBIO in Q1 2020 and held it in 10 quarters. The position peaked at $493K in Q4 2021. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

Cutler Group reported no remaining BridgeBio Pharma position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 300 BridgeBio Pharma shares in Q4 2023, an estimated $7K.
Cutler Group first reported a position in BridgeBio Pharma in Q1 2020 and held it in 10 quarters.
Cutler Group's BridgeBio Pharma position peaked at $493K in Q4 2021.
247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.